All News
Dr O'Brien on co-existent AAV and RA. Not something I'm used to seeing, but maybe we need to think about it more? 25 cases with RA+AAV, 52 with RA + ANCA but no AAV, not sure what the denominator is here though. Abstr#0428 #ACR21 @RheumNow @profgayecunnane https://t.co/fN3BRpc7UJ
Richard Conway RichardPAConway ( View Tweet)
Cluster analysis in axSpA pts classified 2 groups (predominantly axial vs peripheral dz) and showed lower TNFi drug survival rates in those with prominent extra-axial manifestations. Abs 0365 #ACR21 #RheumNow @RheumNow https://t.co/ArgQ7mNqeD https://t.co/XqF7rPneMV
Dr. Rachel Tate uptoTate ( View Tweet)
🔥 Ready for the next level of imaging? The radio-labelled tracer binding to integrin αvβ3 99mTc-maraciclatide is able to detect hypervascularization in RA joints and correlates w/ PDUS findings
⭐️ Sens 78%
⭐️ See 91%
Fancy, yet more invasive than US! #Abst0174 @RheumNow #ACR21 https://t.co/eCOxjJsERh
Aurelie Najm AurelieRheumo ( View Tweet)
3/4 axSpA EMAS pts had/perceived to have employment challenge. Poor physical/mental health, lower education, hx job change due to axSpA associated w/difficulties/perceived difficulties. Earlier dx/rx AND advocacy needed. Abs 0366 #ACR21 #RheumNow @RheumNow https://t.co/dlGhOymxVQ https://t.co/CWD6U1vRE0
Dr. Rachel Tate uptoTate ( View Tweet)
#ACR21 Previews from Creaky Joints
https://t.co/9T3EepV3CE https://t.co/Ay0A3hWSxU
Links:
Dr. John Cush RheumNow ( View Tweet)
Danish axSpA study shows pts in remission on TNFi may be able to taper and remain in remission at the 2 year mark. Abs0364 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/LBR5cSThQY https://t.co/sCqqhuBaTS
Dr. Rachel Tate uptoTate ( View Tweet)
Gender differences in AS pts?
IL-23R, IL-12R, IL-6R, JAK, STAT and TYK2 ⬇️regulated in men
Small study of 20 pts, but could it guide targeted therapy based on gender?🤔
Abs#0050
https://t.co/OQHQCCzfuC
#ACR21
@RheumNow
Links:
Robert B Chao, MD doctorRBC ( View Tweet)
Dr Adachi presents ⬆️BMD gain with denosumab than risedronate in RA. Non-significant reduction in fractures (very small numbers) Interesting, but need to see fracture benefit in larger study to justify dmab as first line Abstr#0445 #ACR21 @RheumNow https://t.co/GgaS9JZGzb
Richard Conway RichardPAConway ( View Tweet)
"I don't want rheumatologist only use BLMB and nephrologist using only VCS."
- Dr. M Petri on how we should work together with nephrologists on managing lupus nephritis.
(She did give a final dig & added "BLMB can be used with any GFR")
#ACR21 #GreatDebate @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
What's the added value of MRI in diagnosing #rheumatoidarthritis among pts w/ undiff'd arthritis?
Accdg to this study by N. Hollander et al, Tenosynovitis was independently assoc'd w/ RA development esp. among ACPA- UA pts 👇
@RheumNow #ACR21 abs0155 https://t.co/F6xlZ1Hy7u
sheila RHEUMarampa ( View Tweet)
Don't forget to discuss Influenza vaccination w/ your RA patients! Higher concerns about RA medications and low necessity of vaccination beliefs associated with a ⬇️ likelihood of vaccination and suboptimal vaccine coverage.
#ACR21 @RheumNow #Abst0141 https://t.co/c5GthZxh3n https://t.co/4Nt92CHFzV
Aurelie Najm AurelieRheumo ( View Tweet)
#GreatDebate: add on BLMB vs. VCS to MMF for LN
Dr. Petri argues for BLMB b/c:
👉cost is less
👉better adherance
👉not good for class V
👉voclosporin had greater nephrotoxicity
👉insuff data in pregnancy, but not contraindicated like VSC #ACR21 @rheumnow https://t.co/mk2eXwkxcG
TheDaoIndex KDAO2011 ( View Tweet)
#ACR21 Great Debate Dr. Brad Rovin:
Voclosporin: Combo with MMF is effective pts of diverse racial and ethnic backgrounds.
⭐️Big plus for a disease with large healthcare disparity issues
@Rheumnow https://t.co/rMpCRPLLGQ
Eric Dein ericdeinmd ( View Tweet)
Abst0385 #ACR21 @RheumNow Serum IL-22 significantly ⬆️ in pts w/ AxSpA (29 pts) vs alternative Dx &healthy (p< 0.001) suggesting serum IL-22 as diagnostic/differential biomarker for AxSpA. levels did not correlate w/mSASSS, BASDAI, ASDAS indices or serum CRP- no prognostic value https://t.co/2B8EWMaSDn
Olga Petryna DrPetryna ( View Tweet)
A cohort study on #uveitis in SpA by @DrDDRheum et al. showed that the axSpA grp had ⬆ incidence of uveitis and ⬆ uveitis flare rates vs. PsA grp.
Predictors of ⬆ risk of new uveitis flare accdg to grp👇
🔸PsA: Male and HLA-B27+
🔸axSpA: ⬆ ESR and CRP
@RheumNow #ACR21 abs0064 https://t.co/8IIET1zcYH
sheila RHEUMarampa ( View Tweet)
RELIANCE observational interim analysis in PFS pts treated w/ CAN. 168 CAPS, TRAPS, HIDS/MKD and FMF pts enrolled starting 10/17 - 12/20. 101 pts experienced an AE, 9 drug-related SAE. See table below. Abs 1090 #ACR21 #RheumNow @RheumNow https://t.co/4ship1G1tY https://t.co/EFlgUGNXdD
Dr. Rachel Tate uptoTate ( View Tweet)
@RADoctor retrospective cohort study, shows RA at ⬆️risk severe COVID-19 outcomes than general population. PsA not at⬆️risk. Abstr#0088 #ACR21 @RheumNow https://t.co/yZ1O5JDJgq
Richard Conway RichardPAConway ( View Tweet)
#ACR21 @RheumNow
Abst#0364 by Wetterslev et al. sought to identify axSpA characteristics of patients tapered off TNFI and showed clinical and radiographic improvement.
🔽52% were tapered off
⭐️The highest predictor of success is a low physician global VAS score
swethaann23 swethaann23 ( View Tweet)
Dr. Rovin at #ACR21 Great Debate:
▶️ Disagrees with Dr. Petri that GFR changes are caused by hemodynamics and is temporary, and non-nephrotoxic
▶️ Voclosporin + MMF is safe
@Rheumnow https://t.co/TxDyprnZ5u
Eric Dein ericdeinmd ( View Tweet)
Freq & severity of adverse events after #SARSCoV2 #vaccine in patients with autoimmune disease vs controls Abs#0104 #ACR21
•No incr. risk of AEs in autoimmune disease vs controls
•Minimal impact of vaccines on disease activity
@RheumNow
https://t.co/jGXP5UL4LP https://t.co/980NLWQYeX
Mrinalini Dey DrMiniDey ( View Tweet)